CL2011000071A1 - Compuestos derivados de oxazolopirimidinas, antagonistas del receptor edg-1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades cardiovasculares, trombosis, aterosclerosis, hipertension, diabetes, enfermedades renales, respiratorias, inflamatorias y autoinmunes, entre otras. - Google Patents
Compuestos derivados de oxazolopirimidinas, antagonistas del receptor edg-1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades cardiovasculares, trombosis, aterosclerosis, hipertension, diabetes, enfermedades renales, respiratorias, inflamatorias y autoinmunes, entre otras.Info
- Publication number
- CL2011000071A1 CL2011000071A1 CL2011000071A CL2011000071A CL2011000071A1 CL 2011000071 A1 CL2011000071 A1 CL 2011000071A1 CL 2011000071 A CL2011000071 A CL 2011000071A CL 2011000071 A CL2011000071 A CL 2011000071A CL 2011000071 A1 CL2011000071 A1 CL 2011000071A1
- Authority
- CL
- Chile
- Prior art keywords
- oxazolopyrimidines
- edg
- thrombosis
- atherosclerosis
- hypertension
- Prior art date
Links
- 201000001320 Atherosclerosis Diseases 0.000 title abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract 2
- 101000693265 Homo sapiens Sphingosine 1-phosphate receptor 1 Proteins 0.000 title abstract 2
- 206010020772 Hypertension Diseases 0.000 title abstract 2
- 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 title abstract 2
- 208000007536 Thrombosis Diseases 0.000 title abstract 2
- BRIOKNPDCPJCOD-UHFFFAOYSA-N [1,3]oxazolo[5,4-d]pyrimidine Chemical class N1=CN=C2OC=NC2=C1 BRIOKNPDCPJCOD-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 230000002757 inflammatory effect Effects 0.000 title abstract 2
- 210000003734 kidney Anatomy 0.000 title abstract 2
- 208000017169 kidney disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000000241 respiratory effect Effects 0.000 title abstract 2
- 208000023504 respiratory system disease Diseases 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08290694 | 2008-07-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2011000071A1 true CL2011000071A1 (es) | 2011-05-06 |
Family
ID=39967817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2011000071A CL2011000071A1 (es) | 2008-07-15 | 2011-01-12 | Compuestos derivados de oxazolopirimidinas, antagonistas del receptor edg-1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades cardiovasculares, trombosis, aterosclerosis, hipertension, diabetes, enfermedades renales, respiratorias, inflamatorias y autoinmunes, entre otras. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8735387B2 (enExample) |
| EP (2) | EP2583720A1 (enExample) |
| JP (1) | JP5449346B2 (enExample) |
| KR (1) | KR20110042286A (enExample) |
| CN (1) | CN102159582B (enExample) |
| AR (1) | AR072496A1 (enExample) |
| AU (1) | AU2009270511B2 (enExample) |
| BR (1) | BRPI0915781A2 (enExample) |
| CA (1) | CA2730843A1 (enExample) |
| CL (1) | CL2011000071A1 (enExample) |
| CO (1) | CO6331436A2 (enExample) |
| IL (1) | IL210639A0 (enExample) |
| MA (1) | MA32455B1 (enExample) |
| MX (1) | MX2011000211A (enExample) |
| NZ (1) | NZ590377A (enExample) |
| RU (1) | RU2503680C2 (enExample) |
| TW (1) | TW201016707A (enExample) |
| UY (1) | UY31981A (enExample) |
| WO (1) | WO2010006704A1 (enExample) |
| ZA (1) | ZA201008786B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI485153B (zh) | 2010-01-13 | 2015-05-21 | Sanofi Aventis | ２，５，７－經取代唑并嘧啶衍生物 |
| TWI478929B (zh) | 2010-01-13 | 2015-04-01 | Sanofi Aventis | 含２，５，７－經取代唑并嘧啶環之羧酸衍生物 |
| AR079885A1 (es) * | 2010-01-14 | 2012-02-29 | Sanofi Aventis | Derivados de oxazolo[5,4-d]pirimidina 2,5-sustituidos utiles para el tratamiento del sindrome del pie diabetico(dfs), composiciones farmaceuticas que los contienen y proceso para prepararlos. |
| PT2523962E (pt) * | 2010-01-14 | 2014-02-06 | Sanofi Sa | Derivados de ácidos carboxílicos com um anel oxazolopirimidina substituído em 2,5 |
| MY156476A (en) * | 2010-01-14 | 2016-02-26 | Sanofi Sa | Heterocyclic carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring |
| CN102791691B (zh) | 2010-03-12 | 2015-06-03 | 日本曹达株式会社 | 含有吡啶环的化合物、及卤代甲基吡啶衍生物以及四唑基肟衍生物的制造方法 |
| US9321787B2 (en) | 2011-07-07 | 2016-04-26 | Sanofi | Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring |
| US8735402B2 (en) * | 2011-07-07 | 2014-05-27 | Sanofi | Cycloalkyloxycarboxylic acid derivatives |
| US8907093B2 (en) * | 2011-07-07 | 2014-12-09 | Sanofi | Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring |
| US8580816B2 (en) * | 2011-07-07 | 2013-11-12 | Sanofi | Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring |
| EP2847200B1 (en) * | 2012-04-26 | 2017-03-29 | Bristol-Myers Squibb Company | Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
| JP6073464B2 (ja) * | 2012-04-26 | 2017-02-01 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 血小板凝集を治療するためのプロテアーゼ活性化受容体４（ｐａｒ４）阻害剤としてのイミダゾチアジアゾールおよびイミダゾピラジン誘導体 |
| US10577308B2 (en) | 2015-03-26 | 2020-03-03 | The Florey Institute | Sodium channel modulators |
| CN117529325A (zh) * | 2021-04-21 | 2024-02-06 | 纳特科药品有限公司 | 制备7-(吗啉基)-2-(N-哌嗪基)甲基噻吩并[2,3-c]吡啶衍生物的改进方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3679682A (en) * | 1970-04-23 | 1972-07-25 | Fmc Corp | CERTAIN 5H-ISOXAZOLO{8 5,4-d{9 PYRIMIDIN-4-ONES |
| US7294633B2 (en) * | 2001-05-14 | 2007-11-13 | Novartis Ag | Oxazolo-and furopyrimidines and their use in medicaments against tumors |
| CA2472680A1 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Selective s1p1/edg1 receptor agonists |
| WO2004096813A1 (en) | 2003-04-25 | 2004-11-11 | University College Cardiff Consultants Limited | Heterocyclic compounds for use in the treatment of viral infections |
| AU2004234067B2 (en) * | 2003-04-30 | 2008-02-28 | Novartis Ag | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators |
| BRPI0410439A (pt) * | 2003-05-19 | 2006-06-06 | Irm Llc | compostos e composições imunossupressoras |
| EP1666468A4 (en) | 2003-09-09 | 2007-03-21 | Ono Pharmaceutical Co | CRF ANTAGONISTS AND HETEROBICYCLIC COMPOUNDS |
| AU2004299456B2 (en) | 2003-12-17 | 2010-10-07 | Merck Sharp & Dohme Corp. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
| US20050165029A1 (en) | 2004-01-13 | 2005-07-28 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
| WO2005123677A1 (en) | 2004-06-16 | 2005-12-29 | Actelion Pharmaceuticals Ltd | 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents |
| WO2006010379A1 (en) | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as immunosuppressive agents |
| JP2008517915A (ja) | 2004-10-22 | 2008-05-29 | メルク エンド カムパニー インコーポレーテッド | Ｓ１ｐ受容体アゴニストとしての２−（アリール）アザシクリルメチルカルボキシレート、スルホネート、ホスホネート、ホスフィネート及びヘテロ環 |
| JP2009520688A (ja) * | 2005-11-23 | 2009-05-28 | エピックス デラウェア， インコーポレイテッド | Ｓ１ｐ受容体調節化合物およびそれらの使用 |
| EP1900729A1 (en) * | 2006-09-15 | 2008-03-19 | Novartis AG | Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors |
-
2009
- 2009-07-02 NZ NZ590377A patent/NZ590377A/en not_active IP Right Cessation
- 2009-07-02 RU RU2011105388/04A patent/RU2503680C2/ru not_active IP Right Cessation
- 2009-07-02 EP EP13151034.9A patent/EP2583720A1/en not_active Withdrawn
- 2009-07-02 EP EP09776914A patent/EP2318415B1/en active Active
- 2009-07-02 US US13/003,125 patent/US8735387B2/en not_active Expired - Fee Related
- 2009-07-02 CN CN200980135883.4A patent/CN102159582B/zh not_active Expired - Fee Related
- 2009-07-02 AU AU2009270511A patent/AU2009270511B2/en not_active Ceased
- 2009-07-02 JP JP2011517773A patent/JP5449346B2/ja not_active Expired - Fee Related
- 2009-07-02 KR KR1020117001113A patent/KR20110042286A/ko not_active Withdrawn
- 2009-07-02 BR BRPI0915781A patent/BRPI0915781A2/pt not_active IP Right Cessation
- 2009-07-02 WO PCT/EP2009/004770 patent/WO2010006704A1/en not_active Ceased
- 2009-07-02 CA CA2730843A patent/CA2730843A1/en not_active Abandoned
- 2009-07-02 MX MX2011000211A patent/MX2011000211A/es active IP Right Grant
- 2009-07-13 TW TW098123561A patent/TW201016707A/zh unknown
- 2009-07-13 AR ARP090102624A patent/AR072496A1/es not_active Application Discontinuation
- 2009-07-13 UY UY0001031981A patent/UY31981A/es not_active Application Discontinuation
-
2010
- 2010-12-07 ZA ZA2010/08786A patent/ZA201008786B/en unknown
-
2011
- 2011-01-05 MA MA33493A patent/MA32455B1/fr unknown
- 2011-01-12 CL CL2011000071A patent/CL2011000071A1/es unknown
- 2011-01-13 IL IL210639A patent/IL210639A0/en unknown
- 2011-01-14 CO CO11003596A patent/CO6331436A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009270511A1 (en) | 2010-01-21 |
| CA2730843A1 (en) | 2010-01-21 |
| CN102159582A (zh) | 2011-08-17 |
| JP5449346B2 (ja) | 2014-03-19 |
| UY31981A (es) | 2010-02-26 |
| EP2318415B1 (en) | 2013-02-20 |
| TW201016707A (en) | 2010-05-01 |
| RU2503680C2 (ru) | 2014-01-10 |
| KR20110042286A (ko) | 2011-04-26 |
| JP2011527994A (ja) | 2011-11-10 |
| ZA201008786B (en) | 2012-01-25 |
| BRPI0915781A2 (pt) | 2015-11-10 |
| US20110190490A1 (en) | 2011-08-04 |
| WO2010006704A1 (en) | 2010-01-21 |
| CO6331436A2 (es) | 2011-10-20 |
| CN102159582B (zh) | 2014-05-07 |
| EP2583720A1 (en) | 2013-04-24 |
| IL210639A0 (en) | 2011-03-31 |
| AR072496A1 (es) | 2010-09-01 |
| MX2011000211A (es) | 2011-03-03 |
| RU2011105388A (ru) | 2012-08-20 |
| NZ590377A (en) | 2011-11-25 |
| US8735387B2 (en) | 2014-05-27 |
| MA32455B1 (fr) | 2011-07-03 |
| EP2318415A1 (en) | 2011-05-11 |
| AU2009270511B2 (en) | 2013-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2011000071A1 (es) | Compuestos derivados de oxazolopirimidinas, antagonistas del receptor edg-1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades cardiovasculares, trombosis, aterosclerosis, hipertension, diabetes, enfermedades renales, respiratorias, inflamatorias y autoinmunes, entre otras. | |
| EA201001253A1 (ru) | N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d | |
| CL2013003333A1 (es) | Compuestos derivados de pregnenolona, antagonistas de receptor cb1; composicion farmaceutica: y su uso para el tratamiento de trastornos de la vejiga y gastrointestinales, enfermedades inflamatorias, cardiovasculares, entre otras. | |
| CL2013000104A1 (es) | Compuestos derivados de heterociclicos nitrogenados sustituidos, agonistas del receptor ip; composicion farmaceutica; combinación farmaceutica; y uso para el tratamiento de la hipertension arterial pulmonar. | |
| ATE526318T1 (de) | Farnesoid-x-rezeptor-agonisten | |
| EA201290940A1 (ru) | Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами | |
| CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
| CL2012000921A1 (es) | Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes. | |
| CL2009000873A1 (es) | Compuestos derivados de ciclohepta[b]piridina, antagonistas del receptor de cgrp; composicion farmaceutica; y uso para el tratamiento de la migrana.b | |
| EA201100133A1 (ru) | Антагонисты рецепторов простагландина d | |
| CL2008001632A1 (es) | Compuestos derivados de acidos benzoilamino-indan-2-carboxilicos sustituidos, inhibidores del receptor cxcr5; composicion farmaceutica; y su uso en el tratamiento de efecciones fisiologicas inflamatorias, tales como artritis reumatoidea y asma. | |
| EA201100306A1 (ru) | Производные циклогексиламида и их применение в качестве антагонистов рецептора crf-1 | |
| CL2007001885A1 (es) | Compuestos derivados de urea de tropano, moduladores de la actividad de la 11betahsd1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como obesidad, diabetes, hipertension, aterosclerosis, demencia y osteoporosis. | |
| EA201170227A1 (ru) | Имидазолкарбоксамиды | |
| EA201071169A1 (ru) | ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3 | |
| EA201001680A1 (ru) | Соединения бензолсульфонамидтиазола и оксазола | |
| CL2011000662A1 (es) | Compuestos derivados de n-heteroaril-sulfonil-amida, moduladores selectivos del receptor cb2; composicion farmaceutica; y uso para el tratamiento del dolor, enfermedad pulmonar,enfermedad autoinmune, enfermedad neurologica, entre otras. | |
| CL2011002942A1 (es) | Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| CL2008000690A1 (es) | Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras. | |
| CL2011003147A1 (es) | Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer. | |
| EP4268814A3 (en) | Pharmaceutical composition for the treatment of dry eye | |
| ECSP088874A (es) | Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual | |
| EA201291180A1 (ru) | Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6) | |
| CL2009000116A1 (es) | Compuestos derivados de heterotriciclos sustituidos, antagonistas del receptor crf; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento de trastornos afectivos, depresion, ansiedad y sindrome del colon irritable. | |
| ECSP099675A (es) | Compuestos heterocíclicos, composición y métodos de uso |